Blood Advances in a Different Vein

Blood Advances in a Different Vein

Research from recent issues of Blood Advances

The MAGIC Marker: Measurements of Two Serum Biomarkers Predict GVHD Treatment Response

Measuring damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD) via the Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP)...

Early Peripheral Blast Cell Clearance Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia

Early peripheral blast cell clearance (PBC) assessed by leukocyte differential is well established as a predictor of leukemia induction outcome, but measuring PBC by...

Defining the Goals of Venetoclax Treatment in Relapsed/Refractory CLL

Achieving undetectable measurable residual disease (MRD) predicts a better clinical outcome in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax,...

Shifting From Eligibility to Optimization of Transplant in Older Adults With Hematologic Malignancies

In an article published in Blood Advances, researchers from the University of Chicago reported efforts to optimize outcomes after hematopoietic cell transplantation (HCT) in...

MRD Response Predicts Survival in Blinatumomab-Treated Patients With Relapsed/Refractory ALL

In patients with relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL) who are treated with blinatumomab, achieving minimal residual disease (MRD) was associated with improved...

Patients’ Humoral Immunity Is Preserved, With Low Rates of Viral Infections, After Anti-CD19 CAR...

The two commercially available chimeric antigen receptor (CAR) T-cell products both target cells expressing the CD19 antigen, which is present on malignant and nonmalignant...

Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia

In a study of children with B-cell acute lymphocytic leukemia (B-ALL) who are about to undergo allogeneic hematopoietic cell transplantation (alloHCT), bridging with blinatumomab...

Certain Non-Hodgkin Lymphoma Subtypes Carry Higher Risk of Infection-Related Solid Tumor Cancers

Various subtypes of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), carry a risk for second infection-related solid...

Can a Patient’s Breath Detect Post-Transplant Gastrointestinal Graft-Versus-Host Disease?

Analyzing the volatile organic compounds (VOCs) expelled in the breath can help clinicians detect and monitor gastrointestinal graft-versus-host disease (GI GVHD) in patients who...

TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML

In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
Advertisement

Current Issue

March 2020, Volume 6, Issue 4

This issue looks at how cost-effective analyses are used to inform health-care decisions, explains the latest maintenance of certification requirements, and more.